Loading…
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $8M | $-513M | $-465M | $-384M | -46.9% | 640.7% | - |
| 2024 | $1M | $-336M | $-298M | $-234M | -22.5% | -74.1% | - |
| 2023 | $4M | $-222M | $-215M | $-173M | -39.8% | -15.3% | - |
| 2022 | $5M | $-167M | $-164M | $-117M | -51.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 4.74 | 4.01 | 1.04 | 7.70 |
| Cost Of Revenue | 0 | 0 | 0 | 1.08 |
| Gross Profit | 0 | 4.01 | 1.04 | 6.62 |
| Operating Expense | 172.62 | 226.62 | 339.89 | 523.39 |
| Operating Income | -167.88 | -222.61 | -338.85 | -516.77 |
| EBITDA | -166.90 | -221.51 | -336.07 | -512.88 |
| EBIT | -167.88 | -222.61 | -338.85 | -516.77 |
| Pretax Income | -163.92 | -214.53 | -298.41 | -465.14 |
| Tax Provision | 0 | 0 | 0 | 0.18 |
| Net Income | -163.92 | -214.53 | -298.41 | -465.32 |
| Net Income Common Stockholders | -163.92 | -214.53 | -298.41 | -465.32 |
| Total Expenses | 172.62 | 226.62 | 339.89 | 524.47 |
| Interest Income | 4.32 | 13.44 | 41.44 | 51.99 |
| Research And Development | 130.22 | 168.53 | 240.16 | 332.06 |
| Selling General And Administration | 42.39 | 58.09 | 99.74 | 191.33 |
| Normalized EBITDA | -167.50 | -221.51 | -336.07 | -512.88 |
| Normalized Income | -164.52 | -214.53 | -298.41 | -465.32 |
| Basic EPS | -3.15 | -3.69 | -3.69 | 0 |
| Diluted EPS | -3.15 | -3.69 | -3.69 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0.21 |
| Total Unusual Items | 0.60 | 0 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | 0.60 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -163.92 | -214.53 | -298.41 | -465.32 |
| Reconciled Depreciation | 0.98 | 1.10 | 2.79 | 3.89 |
| Reconciled Cost Of Revenue | 0 | 0 | 0 | 1.08 |
| Net Interest Income | 4.32 | 13.44 | 41.44 | 51.99 |
| Net Income From Continuing And Discontinued Operation | -163.92 | -214.53 | -298.41 | -465.32 |
| Total Operating Income As Reported | -167.88 | -222.61 | -338.85 | -516.77 |
| Diluted Average Shares | 51.98 | 58.07 | 80.78 | 0 |
| Basic Average Shares | 51.98 | 58.07 | 80.78 | 0 |
| Diluted NI Availto Com Stockholders | -163.92 | -214.53 | -298.41 | -465.32 |
| Net Income Including Noncontrolling Interests | -163.92 | -214.53 | -298.41 | -465.32 |
| Net Income Continuous Operations | -163.92 | -214.53 | -298.41 | -465.32 |
| Other Income Expense | -0.35 | -5.36 | -0.99 | -0.36 |
| Other Non Operating Income Expenses | 0.06 | -0.16 | -0.52 | -0.36 |
| Earnings From Equity Interest | -1.01 | -5.20 | -0.47 | 0 |
| Gain On Sale Of Security | 0.60 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 4.32 | 13.44 | 41.44 | 51.99 |
| Interest Income Non Operating | 4.32 | 13.44 | 41.44 | 51.99 |
| General And Administrative Expense | 42.39 | 58.09 | 99.74 | 191.33 |
| Other Gand A | 42.39 | 58.09 | 99.74 | 191.33 |
| Operating Revenue | 4.74 | 4.01 | 1.04 | 7.70 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals, Inc.this co. | CRNX | $4.0B | - | 3.70 | -46.9% | -5.94 |
| Amicus Therapeutics, Inc. | FOLD | $4.5B | - | 16.43 | -9.9% | 112.00 |
| Dianthus Therapeutics, Inc. | DNTH | $4.5B | - | 7.31 | -32.9% | -18.62 |
| Alignment Healthcare, Inc. | ALHC | $4.5B | - | 24.74 | -0.4% | 90.31 |
| Option Care Health, Inc. | OPCH |
| $4.2B |
| 21.16 |
| 3.18 |
| 15.7% |
| 12.82 |
| iRhythm Holdings, Inc. | IRTC | $4.0B | - | 25.53 | -29.2% | -132.48 |
| Travere Therapeutics, Inc. | TVTX | $3.7B | - | 31.75 | -22.2% | -1780.31 |
| Twist Bioscience Corporation | TWST | $3.5B | - | 7.62 | -16.4% | -30.08 |
| Oruka Therapeutics, Inc. | ORKA | $3.4B | - | 7.07 | -22.5% | -24.94 |
| Peer Median | - | 21.16 | 12.02 | -19.3% | -21.78 | |